Probiotic strain reduces risk of GI infection in infants born by C-section, says recent study

Article

The data showed that infants who received the probiotic strain saw a significant 73% reduction in gastrointestinal infections, compared to the control group.

Photo © stock.adobe.com/ucchie79

Photo © stock.adobe.com/ucchie79

A probiotic strain isolated from breast milk called LC40 (Limosilactobacillus fermentum CECT 5716), has been found in a recent study to reduce the incidence of gastrointestinal infections in infants born by cesarean section (C-section). C-section can disrupt the natural microbiota colonization in infants, potentially compromising their immune system maturation, leading to a higher risk of infection. Researchers evaluated the effects of the probiotic strain on the incidence of gastrointestinal and respiratory infections in a C-section infact subgroup of 173 subjects from three randomized clinical trials. The data showed that infants who received the probiotic strain saw a significant 73% reduction in gastrointestinal infections, compared to the control group.

“Infectious diseases are the most common type of illness in infants, and there’s evidence that they’re more common following C-section deliveries. Clinical studies have already shown that the inclusion of LC40 in formula can significantly reduce the risk of infection,” said Ruth Blanco, head of clinical research at Biosearch Life, a Kerry (Beloit, WI) company, in a press release. “The reason this new analysis is so exciting is that it indicates that the effect it offers is even greater in infants delivered by C-section – demonstrating huge potential for formulas that help reduce infection in a group that can be at higher risk.”

Reference

Blanco-Rojo R et al. “Beneficial effects of Limosilactobacillus fermentum CECT 5716 administration to infants delivered by cesarean section.” Frontiers in Pediatrics, vol. 10 (2022): 906924, https://doi.org/10.3389%2Ffped.2022.906924

Related Videos
woman working on laptop computer by window
Related Content
© 2024 MJH Life Sciences

All rights reserved.